Gilead and Tango Announce Collaboration in Targeted Immuno-Oncology Treatments

On October 31, 2018, Gilead Sciences and Tango Therapeutics, a Massachusetts-based start-up that uses CRISPR and other tools to discover synthetic lethal gene pairs, announced a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Wilson Sonsini Goodrich & Rosati is representing Tango Therapeutics in the transaction.

Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have options to worldwide rights on up to five targets emerging from Tango's proprietary functional genomics-based discovery platform. For two programs directed to these targets, Tango will retain the option to co-develop and co-detail in the U.S. The collaboration does not include Tango's lead programs, for which Tango will retain all rights.

"Tango has built a unique discovery platform that we hope will help create the next generation of cancer therapies," said John McHutchison, AO, MD, Gilead's Chief Scientific Officer and Head of R&D. "Our collaboration will combine Tango's innovative discovery technology alongside Gilead's drug discovery and development capabilities to build a pipeline of novel immuno-oncology therapies."

In this agreement, Tango will receive an upfront payment of $50 million. Tango will also be eligible to receive approximately $1.7 billion in total additional payments across all programs in the form of pre-clinical fees and development, regulatory and commercial milestone payments, and up to low double-digit tiered royalties on net sales. For those programs that Tango opts in to co-develop and co-detail, the parties will split profits and losses 50/50 for the U.S., development costs will be shared in a manner that is commensurate with product rights, and Tango will be eligible to receive milestone payments and royalties on ex-U.S. sales.

The WSGR team representing Tango Therapeutics in the transaction includes partner Farah Gerdes and associate Sarah Parker.

For additional information, please see the official joint press release.